Cell & Gene Exchange, May 2017: ORIG3N

June 16, 2017
ORIG3N exists at the intersection of biological science and emerging technology. Our research team uses cutting-edge cellular science to develop personalized therapies for repairing tissue damage and treating disease. We have an allogenic cell platform technology that allows us to manufacture cell therapies for up to 90% of the US population based on their unique immune profile. We are developing multi-dose, off-the-shelf, cells for neurology and cardiology indications. We are currently looking for partners in these and other therapeutic areas. Additionally, through our DNA tests and community events, we help people understand the links between their genes and how their minds and bodies work. Together with our community, we’re on a mission to accelerate the future of regenerative medicine. Find out more at: www.orig3n.com. Speaker: Marcie Glicksman – Chief Scientific Officer
Previous Video
Cell & Gene Exchange, May 2017: Fibrocell Science, Inc.
Cell & Gene Exchange, May 2017: Fibrocell Science, Inc.

Fibrocell Science, Inc. (NASDAQ: FCSC) is an autologous cell and gene therapy company translating personali...

Next Video
Cell & Gene Exchange, May 2017: Calimmune, Inc.
Cell & Gene Exchange, May 2017: Calimmune, Inc.

Calimmune is accelerating the promise of stem cell gene therapy to liberate patients from chronic and curre...